Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astra Pulmicort Respules

Executive Summary

Asthma product designated "approvable" by FDA Feb. 11. The NDA (20-929) for the new dosage form of Pulmicort (budesonide) was submitted in November 1997. An advisory committee review of the product had been scheduled in April 1998, but was postponed

You may also be interested in...



AstraZeneca Sales Restructuring To Stimulate Respiratory Area, CEO Says

AstraZeneca's sales and marketing restructuring should stimulate growth in the company's respiratory drug portfolio, CEO Tom McKillop maintained during an Aug. 3 briefing in London.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel